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Dengue virus infection of primary endothelial cells (EC) induces innate immune responses, 1 
changes in EC function and is restricted by interferon stimulated responses. 2 
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Abstract 1 
Although endothelial cell (EC) infection is not widespread during dengue virus (DENV) infection in 2 
vivo, the endothelium is the site of the pathogenic effects seen in severe DENV disease.  In this study 3 
we investigated DENV infection of primary EC and defined factors that influence infection in this cell 4 
type. 5 
Consistent with in vivo findings where EC infection is infrequent, only 3-15% of EC became 6 
productively DENV-2-infected in vitro.  This low level infection could not be attributed to inhibition 7 
by heparin, EC donor variation, heterogeneity, or biological source.  DENV-infection of EC was 8 
associated with induction of innate immune responses, including increased STAT1 protein, STAT1- 9 
phosphorylation, and IFN-β, OAS-1, IFIT-1/ISG56 and viperin mRNA.  Antibody blocking of IFN-β 10 
inhibited the induction of OAS1, IFIT1/ISG56 and viperin while shRNA knockdown of viperin 11 
enhanced DENV-infection in EC.  DENV-infection of EC resulted in increased activity of 12 
sphingosine kinase 1, a factor important in maintaining vascular integrity, and altered basal and 13 
stimulated changes in barrier integrity of DENV-infected EC monolayers. 14 
Thus, DENV productively infects only a small percentage of primary EC but this has a major 15 
influence on induction of IFN-β driven innate immune responses that can restrict infection while the 16 
EC themselves are functionally altered.  These changes may have important consequences for the 17 
endothelium and are reflective of pathogenic changes associated with vascular leakage, as seen in 18 
DENV disease. 19 
  20 
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Introduction 1 
Dengue virus (DENV) can infect endothelial cell lines (Avirutnan and others 1998; Basu and others 2 
2011; da Conceicao and others 2013) and primary endothelial cells (EC) derived from a number of 3 
different sources in vitro (Arevalo and others 2009; Bunyaratvej and others 1997; Dalrymple and 4 
Mackow 2011; Huang and others 2000), but the significance of DENV infection of the endothelium in 5 
vivo and the roles of this in DENV pathogenesis has been debated (Basu and Chaturvedi 2008; 6 
Dalrymple and Mackow 2012b; 2014; Martina and others 2009; Spiropoulou and Srikiatkhachorn 7 
2013; Trung and Wills 2010).  Mouse models have shown that DENV infection of the endothelium is 8 
linked to vascular leakage (Chen and others 2007; Yen and others 2008; Zellweger and others 2010) 9 
and human studies have detected the presence of DENV-infected EC in post-mortem samples from 10 
infected patients (Balsitis and others 2009; Jessie and others 2004; Povoa and others 2014).  The low 11 
number of DENV-infected EC along with the lack of overall damage to the EC observed in these 12 
post-mortem samples and rapid and full recovery of many DENV patients with vascular leakage has 13 
favoured a model where the vascular changes associated with severe DENV are primarily due to 14 
indirect effects following infection, mediated by changes in circulating cytokines and chemokines.  15 
Many studies have described low level DENV-infection of primary EC (Anderson and others 1997; 16 
Arevalo and others 2009; Bunyaratvej and others 1997; Diamond and others 2000a; Huang and others 17 
2000; Liu and others 2009; Warke and others 2003) or EC lines in vitro (Peyrefitte et al., 2006).  18 
More recently, up to 90% of human umbilical vein endothelial cells (HUVEC) were DENV infected 19 
when heparin, a common inclusion in culture medium following isolation of primary HUVEC, was 20 
removed from culture (Dalrymple and Mackow 2011), suggesting most HUVEC are susceptible to 21 
DENV but infection is inhibited by heparin.  Microarray analysis has demonstrated up-regulation of a 22 
number of cytokines, chemokines and interferon stimulated genes (ISGs) in DENV-infected EC 23 
(Dalrymple and Mackow 2012a; Warke and others 2003).  Antibody blocking studies have suggested 24 
that it is the action of IFN-β that induces these ISGs and limits DENV infection (Dalrymple and 25 
Mackow 2012a).  Thus, the literature is conflicting on the degree of susceptibility of ECs to DENV 26 
infection, but suggests that EC can be infected by DENV that induces an inflammatory response in 27 
these cells with a central role for IFN-β. 28 
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 1 
In the current study we have extended this understanding of DENV infection of EC.  Using primary 2 
ECs derived from two different sources and multiple EC donors we demonstrate a productive DENV-3 
2 infection in only a small percentage of cells.  DENV-infection of EC was accompanied by early 4 
innate immune responses, including the induction of IFN-β mRNA and the ISG viperin, which acts to 5 
restrict viral infection.  Importantly, even in the face of only a small percentage of productively 6 
DENV-infected EC, we observe a clear change in cellular protein and mRNA profiles related to the 7 
host innate immune response and altered EC function.  Our data suggest that EC may not be a major 8 
target for DENV infection but the responses to this low level DENV infection in EC are reflective of 9 
pathogenic changes in the vasculature and may have important consequences for vascular leakage and 10 
DENV disease in vivo. 11 
 12 
Materials and Methods 13 
HUVEC and ECFC.  Human umbilical cords and cord blood were collected with informed consent 14 
and in line with Central Northern Adelaide Health Service human ethics approval and in accordance 15 
with the ‘Declaration of Helsinki’.  Primary HUVEC were isolated by collagenase digestion of human 16 
umbilical veins, cultured on gelatin (Sigma) coated flasks in M199 media (Sigma) supplemented with 17 
20% (v/v) fetal calf serum (FCS) (Hyclone, Utah, USA), penicillin, streptomycin, 20mM HEPES, 18 
1.5% (w/v) sodium pyruvate (all Gibco, MD, USA), non-essential amino acids (Sigma) and 19 
endothelial cell growth supplement (BD Bioscience) (HUVEC medium) as previously described 20 
(Litwin and others 1997).  HUVEC were utilised in infection studies at passage 1-4. 21 
 22 
Endothelial colony forming cells (ECFC), formerly known as late outgrowth endothelial progenitor 23 
cells were isolated by CD133 magnetic bead isolation of cells from human umbilical cord blood 24 
collected and processed as previously described (Appleby and others 2012).  CD133- mononuclear 25 
cells were then cultured in EGM-2 endothelial growth media (Lonza, Switzerland) supplemented with 26 
an EGM2 bullet kit (Lonza) without heparin and 20% (v/v) FCS.  Further culture, isolation of 27 
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colonies and passaging occurred as previously described (Ingram and others 2004).  ECFC were 1 
utilised at passages 4-8. 2 
 3 
DENV infection and plaque assay.  Cells were infected at a multiplicity (MOI) of 1 for 90 mins 4 
using Mon601, a laboratory clone of the DENV type-2 (DENV-2) strain New Guinea C (Gualano and 5 
others 1998).  Virus stocks were produced from in vitro transcribed RNA that was transfected into 6 
baby hamster kidney (BHK-21) cells and supernatant amplified in C6/36 insect cells.  Titre of virus 7 
stocks and cell culture supernatant samples was determined by plaque assay on Vero, African Green 8 
monkey kidney cells.  Plaques were detected by neutral red overlay and quantitated as pfu per ml.  For 9 
IFN-β blocking studies HUVEC were infected at an MOI of 1 then cultured pi in media supplemented 10 
with control or neutralising IFN-β antibody (Pbl interferon source) at 1000 U/ml. 11 
 12 
RNA extraction and RT-PCR.  Total RNA was extracted from cells using Trizol (Gibco) and 13 
subjected to reverse transcription using random hexamers (NEB).  cDNA was subjected to real time 14 
PCR as follows: DENV primers, 5.1 GCAGATCTCTGATGAATAACCAAC and 3.2: 15 
TTGTCAGCTGTTGTACAGTCG; IFN-β primers, TGTCAACATGACCAACAAGTGTCT and 16 
GCAAGTTGTAGCTCATGGAAAGAG; OAS-1 primers, TCCACCTGCTTCACAGAACTACA and 17 
GGCGGATGAGGCTCTTGAG; IFIT-1 primers, AACTTAATGCAGGAAGAACATGACAA and 18 
CTGCCAGTCTGCCCATGTG; viperin primers, GTGAGCAATGGAAGCCTGATC and 19 
GCTGTCACAGGAGATAGCGAGAA.  Semi-quantitative RT-PCR was performed by amplification 20 
of a standard curve in parallel and results were normalised against cyclophilin quantitated using 21 
primers GGCAAATGCTGGACCCAACACAAA and CTAGGCATGGGAGGGAACAAGGAA.  22 
Reactions were performed in a Corbett Rotorgene 6000 using sybergreen reaction mix (iTaq, 23 
BioRad). 24 
 25 
Immunostaining and confocal microscopy.  Cells were grown on gelatin coated coverslips, fixed in 26 
4% (w/v) paraformaldehyde and stored at 4
o
C.  Fixed cells were permeabilised, blocked and 27 
immunostained for dsRNA (goat anti-mouse antibody at 1/200 dilution, English and Scientific 28 
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Consulting, J2), DENV antigen (DENV patient sera at 1/5000 dilution), as described previously (Carr 1 
and others 2013).  Bound antibody was detected with goat-anti mouse-555 (red) or goat-anti human-2 
488 (green), nuclei were stained with Hoechst (5ug/ml, blue) and images captured by confocal 3 
microscopy (Leica Sp5 Spectral Confocal Microscope). 4 
 5 
Crystal violet staining.  Cell were fixed and stained in 50% methanol containing 0.2% (w/v) crystal 6 
violet.  Unbound stain was removed and fixed cells washed extensively with water.  Bound stain was 7 
solubilised with 2% (w/v) SDS and absorbance at 540 nm was quantitated (Titertek Twinreader). 8 
 9 
SDS-PAGE and Western blotting.  Cells were lysed in passive lysis buffer (Promega) with protease 10 
inhibitors (Roche CompleteMini) and protein levels quantitated (Biorad).  15ug of total protein was 11 
subjected to SDS-PAGE, proteins transferred to nitrocellulose membranes and membranes serially 12 
probed for STAT1-Y701 (Cell Signalling), STAT1-S727 (Cell Signalling), total STAT1 (Cell 13 
Signalling) and actin (Millipore).  Bound antibody complexes were detected by chemiluminesence 14 
(Biorad), images captured (LAS4000, Fuji Film) and quantitated using Image J (Schneider and others 15 
2012). 16 
 17 
shRNA production and infection of HUVEC.  Viperin and control shRNA lentivirus was made as 18 
previously described (Helbig and others 2011).  Following filtration of cultured media from lentivirus 19 
transduced cells through a 0.45 um filter, the viral supernatants were diluted 1:3 in HUVEC media 20 
(M199 media containing the supplements described above) and incubated with HUVEC for 8h.  21 
Lentivirus containing supernatant was removed and replaced with fresh HUVEC media and cells 22 
incubated for approximately a further 64h, prior to DENV infection, as above. 23 
 24 
SK1 activity assay.  Cells were lysed and SK1 activity quantitated by transfer of 
32
P to sphingosine in 25 
vitro, as described previously (Carr and others 2013; Pitman and others 2012).  Total protein was 26 
quantitated (Biorad protein assay) and results expressed as SK1 activity/ug of protein. 27 
 28 
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EC permeability assay.  Cells were DENV or mock infected (heat inactivated virus, 80
o
C, 20 mins) 1 
at an MOI=1, as described above, trypsinised and replated in complete HUVEC medium at 15,000 2 
cells/well in 16 well E-view plates (ACEA Biosciences Inc).  Cells were allowed to recover in 3 
complete HUVEC media and media changed at 2-3h post plating.  Plates were incubated and the cell 4 
index measured by an impedence based real time cell analysis using the x-celligence system (ACEA 5 
Biosciences Inc).  Prior to plating, E-plates were normalised with medium alone and measurements 6 
were taken every hour.  In relevant experiments, at 3h pi, media was changed to M199 + 0.1% (v/v) 7 
FCS, without growth factors and cells incubated overnight.  At 24h pi media was changed to test 8 
stimulus (i) complete HUVEC media or (ii) M199 + 0.1% (v/v) FCS + 0.5 ng/ml recombinant human 9 
TNF- (ProSpec).  Cells were incubated for a further 12h and cell index measured hourly. 10 
 11 
Statistical analysis.  Normally distributed data sets were compared using an unpaired Student’s t-12 
tests.  Experiments were replicated as indicated in each figure legend.  Statistical analysis was 13 
performed using Microsoft Excel. 14 
 15 
Results 16 
Dengue virus productively infects only a small percentage of EC including ECFC.  Recent 17 
studies have shown that heparin inhibits DENV infection of HUVEC and that by 24h pi, the majority 18 
of HUVEC can become DENV-antigen positive (Dalrymple and Mackow 2011).  To assess this in 19 
freshly isolated primary HUVEC, we cultured these cells in the presence or absence of heparin, 20 
DENV-infected and measured infectious virus release by plaque assay.  Results confirm increased 21 
DENV-infection in the absence of heparin (Figure 1A), but still only a low percentage of the total cell 22 
population was observed to be DENV-antigen positive (Table 1).  DENV-infection at a higher MOI of 23 
5 produced a modest increase in infectious virus release (data not shown) and HUVEC showed 24 
slightly higher infected cell numbers when using an alternative DENV-2 strain, POU-312 (Table 1).  25 
Overall, however the percentage of DENV-antigen positive cells was still low and in the order of 3-26 
15% (Table 1). 27 
 28 
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We considered that this low susceptibility of EC to DENV-2 infection noted above could be due to 1 
donor variation, heterogeneity in the primary HUVEC population or variation in EC susceptibility due 2 
to the location in the body they are isolated from.  To address this we next DENV-infected primary 3 
HUVEC, endothelial colony forming cells (ECFC) and Vero cells, a control DENV-susceptible cell 4 
type and quantitated DENV-infection by plaque assay.  ECFC represent a second novel source of 5 
primary EC and are derived clonally from a single circulating EC progenitor.  Both HUVEC and 6 
ECFC demonstrated productive DENV-infection, comparable to Vero cells (Figure 1B).  DENV-7 
infection was highest early (days 24-72h post infection, pi) and persisted but declined with time.  No 8 
cytopathic effect (CPE) was associated with DENV-infection of primary HUVEC or ECFC cultures, 9 
determined visually or as quantitated by crystal violet vital dye staining (Figure 1C).  In contrast, 10 
DENV-infection of Vero cells produced infectious DENV (Figure 1B) but by day 3 pi, a clear visual 11 
DENV-induced CPE was observed with a reduction in vital dye staining (Figure 1C).  The level of 12 
DENV-2 infectious virus release was comparable in cell preparations from different EC donors, 13 
although some donor variation was observed (Figure 1B, D).  DENV-infected cultures from multiple 14 
donors supported active DENV-2 replication, as measured by high DENV titres and the presence of 15 
DENV-2 RNA by RT-PCR at day 2 pi (Figure 1D).  Additionally, dual DENV-2 antigen and dsRNA 16 
positive EC were observed by immunostaining and fluorescence microscopy (Figure 1E).  The 17 
DENV-infection was restricted to a small number of cells and did not spread throughout the entire 18 
culture (Figure 1E).  The number of DENV-infected cells was quantitated by cell counting from 19 
multiple EC donors and observed to be in the range of 3-15% (Table 1), much lower than the routine 20 
infection of the majority of Vero cells under the same conditions (data not shown).  Thus, primary EC 21 
from 2 different sources and multiple donors are susceptible to a low level productive DENV-2 22 
infection in vitro. 23 
 24 
DENV infection of EC induces innate immune responses that restrict DENV-2 infection.  To 25 
assess the ability of DENV-2 to initiate an innate immune response in EC we investigated the 26 
phosphorylation status of STAT1, a key molecule in IFN signalling.  Results demonstrate a clear time 27 
and MOI dependent induction of STAT1-Y701 and S727 phosphorylation in DENV-infected EC from 28 
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24h pi and still elevated at 72h pi (Figure 2).  Interestingly, we also observed an increase in total 1 
STAT1 protein (Figure 2).  We next assessed the up-regulation of IFN-β mRNA and a number of 2 
known anti-viral effector ISGs (IFIT-1/ISG56, OAS-1, and viperin) in response to DENV-2 infection 3 
of EC by RT-PCR.  DENV infection was confirmed by the detection of DENV RNA, which increased 4 
from 24-72h pi (Figure 3A) and was detected in all cases and in multiple EC donors at 48h pi (Figure 5 
3B).  The levels of IFN-β, IFIT-1/ISG56, OAS-1, and viperin mRNAs were undetectable or negligible 6 
in mock-infected cells (Figure 3).  IFN-β was induced in DENV-infected cells at 24h pi and still 7 
present at 72h pi (Figure 3A).  Levels of IFN-β mRNA, were elevated at 48h pi in all cases and in 8 
multiple EC donors (Figure 3B).  In contrast, mRNA for IFIT1/ISG56, OAS-1 and viperin were all 9 
induced in DENV-infected cells at 24h pi, further elevated at 48h pi but declining by 72h pi (Figure 10 
3A).  Again elevated mRNA levels at 48h pi were observed in all cases and in multiple EC donors 11 
(Figure 3B).  These results indicate that a robust innate antiviral response is initiated in EC cells 12 
following DENV infection. 13 
 14 
Cells were next infected with DENV-2 and incubated with a neutralising antibody against IFN-β.  At 15 
48h pi cells were fixed for immunostaining and RNA extracted for RT-PCR.  At 48h pi DENV-2 16 
infection was enhanced in HUVEC incubated with antibody against IFN-β, as measured by 17 
production of DENV-2 RNA by RT-PCR (Fig 4A) although production of infectious virus was not 18 
significantly different (Fig 4B).  Consistent with this, staining for dsRNA was visualised in increased 19 
numbers of HUVEC in cells treated with the IFN-β antibody but the majority of cells still remained 20 
uninfected (Fig 4C).  Treatment of cells with a neutralising antibody against IFN-β also reduced the 21 
level of mRNA for OAS-1, IFIT1/ISG56 and viperin but not IFN-β itself (Fig 4D).  Immunostaining 22 
of fixed cells for viperin and STAT1-S727 unfortunately was not successful and thus we could not 23 
formally demonstrate if the induction of this response was in DENV-2-infected or uninfected 24 
bystander cells. 25 
 26 
We have previously reported that viperin has anti-viral actions against DENV (Helbig and others 27 
2013) and thus we next investigated the specific role of viperin in restricting DENV infection by 28 
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shRNA-mediated knockdown of viperin in EC.  HUVEC were transduced with a viperin shRNA 1 
lentivirus that has been previously demonstrated to reduce the induction of viperin via IFN- 2 
stimulation by 90-95% (Helbig and others 2011), a control lentivirus or mock transduced.  Cells were 3 
allowed to recover and 3 days later challenged with DENV-2.  A reduction in viperin mRNA levels 4 
was achieved in viperin shRNA compared with control lentivirus transduced cells at day 2 and 3 post 5 
lentivirus transduction (supplementary Fig 1).  Following DENV-2 infection there was a modest 6 
although significant increase in production of infectious virus from viperin shRNA cells at 48h pi 7 
(Figure 5A).  Immunostaining for dsRNA and quantitation by visual cell counting demonstrated an 8 
increased number of infected cells in viperin shRNA cultures, although the majority of EC still 9 
remained uninfected (Figure 5B, Table 2).  This suggests that viperin can inhibit, but does not 10 
completely restrict DENV-2 infection of EC. 11 
 12 
DENV infection of EC induces sphingosine kinase-1 activity and alters EC barrier integrity.  13 
Our prior studies have identified sphingosine kinase-1 (SK-1) as a vital molecule for EC function such 14 
as survival and differentiation (Bonder and others 2009; Gamble and others 2009) that we know is 15 
also altered during DENV infection (Carr and others 2013; Wati and others 2011).  We thus 16 
quantified SK1 activity in DENV-infected EC lysates.  At 24h pi, SK1 activity was significantly 17 
increased in DENV-2 infected EC, however, by 48h pi, SK1 activity had normalised and showed no 18 
difference between mock and DENV-2 infected EC (Figure 6). 19 
 20 
The induction of components of the innate immune response (Figure 3) and changes in SK1 activity 21 
(Figure 6) suggest the potential for functional changes in DENV-2 infected EC and we therefore next 22 
assessed the barrier integrity of DENV-2 infected EC monolayers.  HUVEC were mock or DENV-2 23 
infected, then plated in a chamber slide at a density we previously defined to form a monolayer.  The 24 
cell index, which reflects changes in cell number or function was quantified by real time measurement 25 
of electrical impedence using the x-celligence system.  Cell monolayers were viewed by microscopy 26 
using the E-view plate system to confirm cell viability and confluence.  Results were normalised in 27 
each experiment against mock infected controls and demonstrate changes in cell index or barrier 28 
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integrity with time (Figure 7).  The initial barrier integrity of DENV-infected EC appears lower at 1h 1 
post infection, although this is not significant.  The spike at 2h pi reflects a transient change in barrier 2 
integrity due to removal of the chamber slide from the incubator to change the media.  A significant 3 
reduction in cell index, reflecting a decrease in the integrity of the EC barrier, was observed in 4 
DENV-infected EC that subsequently recovered to normal within the first 24h of infection.  This 5 
effect was observed with either EC cultured in complete HUVEC media (Figure 7A) or in low serum 6 
media (0.1% [v/v] FCS; Figure 7B).  Consistent with our prior observations (Figure 1C), in multiple 7 
infection experiments from different EC donors there was no evidence of a visual DENV-associated 8 
CPE. 9 
 10 
EC responses to vasoactive stimuli were also assessed at 24h pi.  EC were DENV-2 infected and 11 
plated in x-celligence chambers, allowed to recover for 3h in complete HUVEC media, then serum 12 
starved overnight (0.1% FCS, no growth factors).  Cultures were then treated with TNF- or re-fed 13 
complete HUVEC media.  Notably, at 24h pi (time 0 for addition of TNF- or complete media) the 14 
barrier integrity of DENV-EC appears reduced, although this is not significant.  At 6-7h post addition 15 
of TNF-, a greater reduction in EC barrier integrity was observed in DENV-2 compared to mock 16 
infected EC (Figure 8A).  In contrast, re-stimulation of EC with 20% FCS/growth factors following 17 
serum starvation, maintained the barrier integrity of the mock-infected EC monolayer for up to 8h, but 18 
that of DENV-infected EC declined (Figure 8B).  Together these results suggest time-dependent 19 
changes in SK-1 activity and functional changes in both basal and growth factor stimulated EC barrier 20 
integrity. 21 
 22 
Discussion 23 
Emerging evidence suggests an important role of the endothelium for innate immune responses during 24 
viral infections that could also be a potential therapeutic target to prevent tissue and vascular damage 25 
(Baccala and others 2014; Oldstone 2013; Safronetz and others 2014; Teijaro and others 2011).  The 26 
role of the endothelium during DENV-infection is not well defined, however the endothelium is a 27 
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clear target for the pathogenesis of disease.  While the degree to which the endothelium contributes to 1 
DENV replication is controversial there are well described functional changes in the endothelium that 2 
are linked to severe DENV disease, (Basu and Chaturvedi 2008; Dalrymple and Mackow 2012b; 3 
2014).  Most studies in primary EC and EC lines demonstrate a low level of EC susceptibility to 4 
productive DENV-infection with anywhere from 2-30% of EC becoming infected within 1-7 days of 5 
infection (Andrews and others 1978; Arevalo and others 2009; Bunyaratvej and others 1997; 6 
Diamond and others 2000a; Huang and others 2000; Liu and others 2009; Peyrefitte and others 2006; 7 
Vervaeke and others 2013; Warke and others 2003; Zamudio-Meza and others 2009).  DENV is 8 
reported to utilise heparin sulphate proteoglycans (HSPG) for entry into a variety of cell types 9 
(Artpradit and others 2013; Chen and others 1997; Germi and others 2002; Hilgard and Stockert 2000; 10 
Lin and others 2002) including EC (Dalrymple and Mackow 2011; Vervaeke and others 2013) and in 11 
the study by Dalrymple and Mackow, DENV-4 infection of EC at MOI of 6 in the absence of heparin 12 
resulted in up to 90% of HUVEC DENV-antigen positive at day 1 pi, as assessed by 13 
immunohistochemistry (Dalrymple and Mackow 2011).  Similarly, in our study, exclusion of heparin 14 
from the cell culture medium increased by 0.5-1.5 log production of infectious virus from DENV-2 15 
infected HUVEC.  However, in our experiments, at best only around 15% of the EC population 16 
became DENV antigen and dsRNA positive.  The study of Vervaeke et al., 2013 utilised primary 17 
dermal microvascular EC or microvascular EC lines infected with DENV-2 (NGC) and achieved 18 
infection of 10-50% of cells in the absence of heparin that was dependent on MOI (Vervaeke and 19 
others 2013), while approximately 40% of commercially acquired HUVEC were reported to become 20 
DENV-2 (16681) infected at day 3-7 pi in the absence of heparin (Raekiansyah and others 2014).  21 
Clearly, heparin inhibits DENV-infection of EC and the discrepancies between studies in the actual 22 
level of EC susceptibility to DENV-infection may be due to technical factors such as EC senescence 23 
(AbuBakar and others 2014), the DENV strain, including potential adaptation to utilise heparin 24 
(Artpradit and others 2013; Celis and others 2014; Lee and others 2006) or the presence of DENV 25 
NS1 in the inoculum which can bind to glycosaminoglycans (GAGs) and heparin (Avirutnan and 26 
others 2007) and may competitively inhibit DENV infection of EC. 27 
 28 
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Regardless, EC are susceptible to DENV infection and in our infection system DENV-2 does not 1 
spread to infect the majority of cells in culture when using EC from multiple donors, representing two 2 
different biological sources of EC and including the novel ECFC type, derived from EC progenitors. 3 
 4 
We confirmed the induction of IFN-β mRNA in DENV-infected EC as previously reported (da 5 
Conceicao and others 2013; Dalrymple and Mackow 2012a; Warke and others 2003).  Additionally, 6 
we report the induction of OAS-1, IFIT1/ISG56, and viperin mRNA as well as an increased level of 7 
both total STAT1 protein and STAT1-S727 and Y701 phosphorylation in DENV-2 infected EC.  The 8 
observation that total STAT1 protein is increased at 72h pi in DENV-2 infected EC is interesting and 9 
may in part account for the increase seen in STAT1 phosphoprotein.  Recent work  has demonstrated 10 
that a second wave of induction of ISGs is generated through a prolonged production of IFN-β, which 11 
could drive an increase in unphosphorylated forms of STAT1, STAT2 and IRF9 (Cheon and others 12 
2013).  Similarly, the production of IFN-β, for which we observed mRNA out to at least 72h pi, may 13 
be responsible for the increased total STAT1 in our study.  As expected, IFN-β blocking experiments 14 
reduced the RNA levels of OAS-1, IFIT1/ISG56 and viperin demonstrating that induction of these 15 
genes is dependent on the action of IFN-β.  Blocking of IFN-β enhanced DENV RNA production and 16 
number of dsRNA containing cells, but not the amount of infectious virus in cell culture supernatants.  17 
This suggests that when IFN-β actions are blocked after infection, production of virus from existing 18 
infected cells is unaltered, as expected (Diamond and others 2000b) but additional cells become 19 
DENV susceptible and new rounds of infection are increased.  These results strongly imply an IFN-β 20 
dependent induction of responses and restriction of infection in bystander cells.   Unfortunately, 21 
immunostaining for endogenous viperin or STAT-1-S727 in HUVEC could not be achieved to 22 
conclusively demonstrate this.  Additionally, lentivirus transduction of EC with shRNA against the 23 
ISG viperin also increased DENV infection..  This result is similar to our described anti-viral role for 24 
viperin against DENV-2 infection in macrophages, another important target cell type for DENV 25 
infection and pathogenesis, and where similarly a low percentage of cells are DENV-infected which is 26 
associated with induction of viperin, particularly in uninfected bystander cells (Helbig and others 27 
2013).  Notably, transduction of viperin shRNA into EC in our study, or blocking with a neutralising 28 
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IFN-β antibody did not result in a complete take-over of the EC culture by the DENV.  We 1 
demonstrated lower levels of viperin mRNA in viperin shRNA cells prior to and at the time of 2 
DENV-infection, have previously validated our viperin shRNA to yield 95% knockdown of IFN-3 
stimulated viperin in Huh7 cells (Helbig and others 2011) and our prior work has shown a high 4 
lentivirus transduction rate of EC (Barrett and others 2011).  Our results herein, however, suggest that 5 
the viperin shRNA knockdown and blocking of IFN-β activity may be incomplete or perhaps 6 
overwhelmed by the strong induction of innate responses by DENV infection of EC.  Additionally, 7 
there are likely to be other anti-viral factors that are IFN-β-independent or unaffected by viperin 8 
shRNA that can still act to restrict infection in these cells, as suggested by the large number of ISGs 9 
that are known to target positive strand RNA viruses in other cell types (Schoggins and others 2014).  10 
Although DENV-infection of EC does not occur in a major fraction of the cell population, the 11 
infection clearly still has a significant effect on EC function.  We demonstrate an increase in SK1 12 
activity at 24h pi, a factor that we have previously shown to be an essential regulator of EC survival, 13 
growth and differentiation (Bonder and others 2009; Gamble and others 2009).  The increase in SK1 14 
activity in DENV-infected EC may reflect a viral-induced response to prevent pre-mature death of 15 
newly infected cells, as has been suggested for the increased SK1 seen early following RSV and 16 
HCMV infection in vitro (Machesky and others 2008; Monick and others 2004).  Additionally, SK1 17 
has been proposed to play a role in influencing the JAK/STAT pathway following IFN signalling to 18 
activate ISGs (Seo and others 2011).  The detected increase in SK1 activity early in DENV infection 19 
differs to our prior work showing reduced SK1 activity late in DENV-infected cells which is mediated 20 
via high levels of the DENV 3’UTR of the genome (Carr and others 2013; Wati and others 2011).  21 
Thus, the increase in SK1 seen early in DENV-infected HUVEC is mechanistically different to the 22 
later decrease in SK1 activity and likely to be driven by anti-viral host responses rather than viral 23 
replication per se. 24 
 25 
Based on our prior work with SK1 and EC, we would expect that elevated levels of SK1 activity 26 
would promote EC barrier integrity (Li and others 2008) and sensitise EC to stimulation with 27 
inflammatory cytokines (Limaye and others 2009).  We assessed this by quantifying real time changes 28 
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in EC barrier integrity in vitro.  Our data demonstrate significantly different changes in EC barrier 1 
integrity in mock and DENV-2 infected EC.  Barrier integrity of DENV-2-infected EC was decreased 2 
in the early hours following infection, was more pronounced in EC grown in the absence of growth 3 
factor supplementation but normalised again by 24h pi.  This suggests an acute response following the 4 
insult of a viral infection where the integrity of the EC barrier is compromised.  The increased SK1 5 
activity we detected at 24h pi may subsequently restore normal vascular barrier function.  6 
Additionally, we observed that DENV-infected EC have altered responsiveness to TNF-α and growth 7 
factor stimuli, as previously reported (Cardier and others 2005; Carr and others 2003; Dewi and others 8 
2004; 2008) and consistent with elevated SK1 activity at 24h pi sensitising cells to the actions of 9 
TNF-α (Limaye and others 2009).  Some prior studies have suggested that DENV-infected EC do not 10 
show altered permeability or responses to stimuli such as TNF- in vitro (Liu and others 2009; 11 
Raekiansyah and others 2014; Talavera and others 2004).  These studies, however, utilised single time 12 
points at later times pi for analysis of barrier integrity (eg. 7 days pi), and thus may have missed the 13 
transient early changes in EC function identified in our study.  The changes in DENV-EC barrier 14 
function we have identified in vitro are likely to have functional implications for the endothelium 15 
during DENV infection in vivo, in particular for relevant biological stimuli, such as TNF-, that are 16 
known to be elevated in the circulation of DENV infected patients. 17 
 18 
In conclusion, we have presented data demonstrating that DENV-2 can productively infect EC, but 19 
infection is restricted and associated with a strong induction of the innate immune response and 20 
functional changes in EC.  These results support the growing evidence for an important role of 21 
DENV-infected EC, not as a major site of viral replication, but as a contributor to the inflammatory 22 
response and functional changes in the endothelium that may be associated with severe DENV-23 
disease in vivo. 24 
 25 
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Figure Legends 12 
Figure 1.  DENV-2 productively infects EC.  HUVEC or ECFC were isolated and mock or DENV-2 13 
infected at an MOI=1.  A. At 24h prior to infection cells from 3 independent cord donors were plated 14 
in media with or without heparin, DENV-2 infected and cultured ± heparin.  Culture supernatant was 15 
collected, clarified and infectious virus release quantitated by plaque assay.  Results represent mean ± 16 
SD from duplicate infections from each donor.  * = p<0.05, Students unpaired t-test.  B.  At the 17 
indicated time point pi, culture supernatant was harvested and infectious virus release determined, as 18 
in A.  Results represent mean ± SD from duplicate infections from each donor.  * = p<0.05, Students 19 
unpaired t-test.  C.  At 72h pi, cells were fixed and stained with crystal violet and A540nm 20 
quantitated.  Results represent mean ± SEM (n=5).  * = p<0.05, Students unpaired t-test.  D.  At 48h 21 
pi, supernatant was collected and infectious virus release determined as in A (left panel).  Cells were 22 
lysed and total DENV RNA quantitated by RT-PCR (right panel).  Results represent single 23 
measurements from individual donors (n=15, pfu/ml) and (n=10, DENV RNA).  E.  At 48h pi cells 24 
were fixed and immunostained for dsRNA (red) and DENV antigen (Ag, green).  Nuclei were stained 25 
with Hoechst (blue) and images captured by confocal microscopy.  Images are representative, 26 
showing very few DENV positive cells in each field and co-staining for dsRNA and DENV Ag. 27 
 28 
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Figure 2.  DENV-2 infection of EC induces STAT1 phosphorylation and total STAT1 protein.  1 
A.  EC were mock or DENV-2 infected at an MOI = 1 or 5 and at 24 and 72h pi, cells were lysed and 2 
subjected to SDS-PAGE and western blot.  Filters were serially probed for STAT1-Y701, S727, total 3 
STAT1 and actin.  Bound proteins were detected by chemiluminesence and images captured.  Images 4 
show results from two independent EC donors and infections.  B.  Images from EC1 were quantitated 5 
using ImageJ and normalised against actin. 6 
 7 
Figure 3.  DENV-2 infection of EC induces innate immune responses.  EC were mock or DENV-2 8 
infected, RNA extracted and subjected to RT-PCR.  Results were normalised against cyclophilin.  A. 9 
Time course for production of DENV RNA and induction of IFN-β, viperin, IFIT1/ISG56 and OAS-10 
1.  Results represent duplicate infections from a single donor.  B.  RT-PCR results from duplicate 11 
infections in multiple donors (n=4-5). 12 
 13 
Figure 4. Blocking of IFN-β actions increases DENV-2 infection and reduces mRNAs for ISGs.  14 
HUVEC were DENV-2 infected and incubated with control or 1000 U/ml of a neutralising antibody 15 
against IFN-β.  At 48h pi cells were lysed and RNA extracted or cells fixed and immunostained.  A.  16 
DENV-2 RNA by RT-PCR; B. infectious virus release by plaque assay; C. dsRNA (green), nuclei 17 
(blue) were stained with Hoechst and images captured by confocal microscopy (i) mock infected, (ii) 18 
control and (iii) IFN-β antibody; D. IFN-β, OAS-1, viperin and IFIT1/ISG56 mRNA detected by RT-19 
PCR.  PCR results were normalised against cyclophilin and are expressed relative to no control 20 
antibody treatment and are representative of duplicate infections from n=2 different HUVEC donors. 21 
 22 
Figure 5.  Viperin shRNA transduction enhances DENV-2 infection of EC.  HUVEC were mock 23 
transduced or transduced with a control or viperin shRNA lentivirus.  At 72h post transduction, EC 24 
were DENV-2 infected and at 48h pi  A. supernatant collected and analysed for infectious virus 25 
release by plaque assay.  Results represent mean ± SD from duplicate infections from 3 different 26 
donors and lentivirus transduction experiments.  *= p<0.05, Student’s unpaired t-test.  B. cells were 27 
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fixed and immunostained for dsRNA (green).  Nuclei were stained with Hoechst (blue) and images 1 
captured by confocal microscopy. 2 
 3 
Figure 6.  SK1 activity is increased early following DENV-2 infection of EC.  EC were mock or 4 
DENV-2 infected and at the indicated time point pi, cells were lysed and SK1 activity quantitated.  5 
Results were normalised against total protein and represent mean ± SEM from duplicate results from 6 
3 independent donor and infection experiments.  *= p<0.05, Student’s unpaired t-test. 7 
 8 
Figure 7.  DENV-2 infection of EC decreases basal barrier integrity in the early hours following 9 
infection.  EC were mock or DENV-2 infected, replated in E-view plates and incubated in the x-10 
celligence with hourly measurements of barrier integrity.  Cells were allowed to recover for 2h, media 11 
changed and incubation continued for a further 22h in either A.  complete HUVEC media or B.  0.1% 12 
(v/v) serum containing media.  Results were normalised against mock-infected control cells and 13 
represent mean ± SEM of n=2-4 measurements at each time point from n=4 independent donors and 14 
infection experiments.  *= p<0.05, Student’s unpaired t-test. 15 
 16 
Figure 8.  DENV-2 infection of EC sensitises EC to stimulation.  EC were mock or DENV-2 17 
infected, plated in E-view plates and allowed to recover for 3h.  Media was changed to 0.1% (v/v) 18 
serum media and cells incubated overnight.  Media was then replaced with A. M199 + 0.1% (v/v) 19 
FCS + 0.5 ng/ml recombinant human TNF- or B. complete HUVEC media (20% [v/v] serum + 20 
endothelial cell growth supplements) and incubated for a further 12h.  Results were normalised 21 
against mock at the time of addition of TNF- or serum (t=0) and represent mean ± SEM of n=6 22 
measurements at each time point from two independent donor and infection experiments.  *= p<0.05, 23 
Student’s unpaired t-test. 24 
 25 
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